Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177lu-psma-r2 + 225ac-psma-r2
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**177Lu-PSMA-R2 (AAA602) and 225Ac-PSMA-R2 (AAA802)** are investigational radioligand therapies targeting the Prostate-Specific Membrane Antigen (PSMA). These agents consist of the PSMA-R2 ligand conjugated to either the beta-emitting radionuclide Lutetium-177 or the alpha-emitting radionuclide Actinium-225. Both drugs are designed to deliver targeted radiation to PSMA-expressing prostate cancer cells, causing lethal DNA damage. They are being evaluated as neoadjuvant treatments before surgery in high-risk localized prostate cancer (HRLPC) and in advanced hormone- and castration-resistant prostate cancer (mCRPC, mHSPC). The theranostic approach enables personalized therapy, where PSMA-R2 labeled with a diagnostic radioisotope (e.g., gallium-68) identifies suitable patients for therapeutic intervention with AAA602 or AAA802[1][2][3][4][7][9].
- Other names
- [177Lu]Lu-PSMA-R2[225Ac]Ac-PSMA-R2
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177lu-psma-r2 + 225ac-psma-r2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177lu-psma-r2 + 225ac-psma-r2.